The Evidence

Small-fiber nerves and MCS: could part of the problem begin outside the brain?

Small-fiber neuropathy is one of the most interesting objective findings in a selected MCS/chronic-pain cohort, but it is not yet an MCS biomarker. A 21-person selected sample cannot establish prevalence. The finding is important because it gives researchers a measurable peripheral-nerve phenotype to test in larger, well-defined cohorts.

A skin-biopsy study found objective small-fiber neuropathy in a selected group of 21 people with MCS and chronic pain. The finding is important, but it is a phenotype clue - not yet a population-wide explanation.

Small-fiber nerve change is a real line of investigation in MCS, and it is not the leading mechanism here. Receptor sensitization is, because it has been tested by provocation in living patients and small-fiber findings have not.

Why small fibers are an unusually interesting clue

Small nerve fibers are the thin sensory and autonomic fibers that carry pain, temperature and internal-body signals and help regulate functions such as sweating and vascular tone. They sit at an important boundary between the environment and the nervous system. That makes small-fiber biology especially relevant to a condition characterized by sensory amplification, pain and multisystem responses.

The 21-person small-fiber study cannot tell us how common small-fiber neuropathy is in MCS because the patients were selected for neurology referral and chronic pain. Within that selected subgroup, however, the finding was striking: all 21 people previously diagnosed with MCS showed somatic small-fiber neuropathy on skin biopsy.

What that study proves - and what it does not

The result is objective. Reduced or abnormal small-fiber innervation on skin biopsy is not a questionnaire response or a belief about exposure. In this selected group, a measurable peripheral nerve abnormality was present.

That result must not be generalized to the whole MCS population. These patients were referred specifically because chronic pain made clinicians suspect small-fiber neuropathy. The study therefore demonstrates an objectively abnormal peripheral-nerve phenotype in a selected MCS subgroup; it does not establish prevalence.

The autonomic detail makes the story more interesting

Eighteen of the 21 patients reported autonomic symptoms. Yet the skin biopsies showed sparing of autonomic innervation while demonstrating somatic small-fiber loss. That means the study did not simply prove a generalized autonomic neuropathy. The relationship among sensory small fibers, autonomic symptoms and MCS remains open.

This distinction matters because it prevents a tempting overclaim. MCS cannot currently be relabeled "small-fiber neuropathy." Small-fiber neuropathy may instead identify one biological phenotype inside a broader MCS population.

How small fibers could fit the environmental-hyperresponsiveness model

A peripheral sensory abnormality could help explain why central-brain-only models are incomplete. Environmental chemicals first encounter peripheral tissues: airway, skin, mucosa and sensory nerve endings. TRPV1, TRPA1 and related receptors are expressed on sensory fibers that detect irritants and noxious signals. If those pathways become sensitized or structurally altered, the input arriving at the brain may already be amplified before prediction or conscious interpretation enters the picture.

That does not mean small-fiber damage is necessarily the initiating lesion. It could be cause, consequence, comorbidity or a marker of susceptibility. But it gives us a testable biological bridge between environmental exposure, peripheral sensation and central processing.

What the registry is answering

The Canary Registry should identify the phenotype most likely to enrich future small-fiber studies: burning pain, unusual temperature sensitivity, altered sweating, orthostatic symptoms, neuropathic sensations, gastrointestinal/autonomic complaints, and strong sensory responses to chemicals.

Future research should compare carefully defined MCS participants with healthy controls and relevant disease controls, not only patients already referred for neuropathy. Skin biopsy should be paired with quantitative sensory testing and autonomic testing so we can ask whether somatic and autonomic small-fiber abnormalities travel together or define separate subgroups.

Where we stand

Small-fiber neuropathy is one of the most concrete peripheral-neurology findings reported in an MCS subgroup. It is important precisely because it is objective - and limited precisely because the study population was highly selected.

The right conclusion is neither "MCS is small-fiber neuropathy" nor "the finding does not matter." The right conclusion is that small-fiber pathology is a serious phenotype candidate that should now be tested systematically in consensus-defined MCS.

We followed the evidence. Here’s where it leads →

Sources

Sources

1Molot J, Sears M, Anisman H. Multiple chemical sensitivity: It's time to catch up to the science. Neuroscience & Biobehavioral Reviews. 2023;151:105227. DOI: 10.1016/j.neubiorev.2023.105227.
2Rossi S, Pitidis A. Multiple Chemical Sensitivity: Review of the State of the Art in Epidemiology, Diagnosis, and Future Perspectives. Journal of Occupational and Environmental Medicine. 2017;60(2):138-146. PMID: 29111991. DOI: 10.1097/JOM.0000000000001215.
3Ternesten-Hasséus E, Bende M, Millqvist E. Increased capsaicin cough sensitivity in patients with multiple chemical sensitivity. Journal of Occupational and Environmental Medicine. 2002;44:1012-1017.
41. Fileccia E, Incensi A, Ventruto F, et al. Small Fiber Neuropathy in Patients with Chronic Pain and a Previous Diagnosis of Multiple Chemical Sensitivity Syndrome. J Neuropathol Exp Neurol 2021;80(9):868-74. PMID: 34402516. https://pubmed.ncbi.nlm.nih.gov/34402516/
← Back to MCSDisability.com
↑